Research ArticleNEUROSCIENCE

An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer’s disease

See allHide authors and affiliations

Science Advances  12 Feb 2016:
Vol. 2, no. 2, e1501244
DOI: 10.1126/sciadv.1501244
PDF Container